Overview
Solitary fibrous tumors of the pleura (SFTPs) are rare neoplasms originating from submesothelial pleural mesothelium. These tumors can range from benign to malignant, posing significant diagnostic and therapeutic challenges due to their varied clinical behavior. While benign SFTPs generally have an excellent prognosis following complete resection, malignant variants may recur or metastasize, necessitating careful risk stratification and follow-up. Given their rarity and potential for aggressive behavior, accurate diagnosis and appropriate management are crucial in clinical practice to ensure optimal patient outcomes 1234.Pathophysiology
The exact molecular mechanisms underlying the development of SFTPs remain incompletely understood, but they are thought to arise from multipotent mesenchymal cells within the pleura. Genetic alterations, including mutations in genes such as NF2 (neurofibromatosis type 2) and CDKN2A, have been implicated in both benign and malignant forms 1. These genetic changes can lead to dysregulation of cell proliferation and differentiation pathways, contributing to tumor growth. Histologically, SFTPs exhibit a distinctive pattern characterized by a proliferation of spindle cells with varying degrees of cellularity, nuclear atypia, and mitotic activity, which are critical in distinguishing benign from malignant tumors. The presence of necrosis, high mitotic rates, and atypical cytology often correlates with a more aggressive clinical course 12.Epidemiology
SFTPs are relatively uncommon, accounting for approximately 0.1% to 0.5% of all pleural neoplasms 1. They predominantly affect adults, with a median age at diagnosis ranging from the 4th to 6th decades, though cases across all age groups have been reported 123. There is no significant gender predilection, with a roughly equal distribution between males and females 12. Geographic distribution does not suggest specific risk factors, indicating that SFTPs occur globally without notable regional clustering. Incidence rates have not shown significant temporal trends, suggesting stable prevalence over time, though larger population studies are needed for definitive conclusions 1.Clinical Presentation
Patients with SFTPs often present with nonspecific symptoms due to the mass effect of the tumor on surrounding structures. Common clinical features include dyspnea, chest pain, and cough, which can mimic other pleural diseases such as pleural effusions or mesothelioma 23. Asymptomatic cases are also reported, particularly in smaller, benign tumors detected incidentally on imaging studies. Red-flag features that may indicate malignancy include rapid tumor growth, significant weight loss, and systemic symptoms like fever or night sweats. Accurate clinical assessment is crucial for timely diagnosis and appropriate management 23.Diagnosis
The diagnostic approach for SFTPs involves a combination of clinical evaluation, imaging, and histopathological analysis. Key steps include:Imaging Studies: Chest CT and MRI are essential for characterizing the tumor's size, location, and relationship to adjacent structures. Pleural thickening and a well-defined mass are typical findings 23.
Biopsy and Histopathology: Definitive diagnosis relies on histopathological examination of tumor tissue. Immunohistochemical markers such as CD34 and vimentin are often positive, aiding in the diagnosis 23.
Recurrence Score: A validated scoring system incorporating factors like pleural origin, morphology, size, cellularity, necrosis, hemorrhage, and mitotic activity can predict recurrence risk 1. A cutoff score of 3 points helps classify patients into low (<3 points) and high (≥3 points) risk categories for recurrence 1.Specific Criteria and Tests:
Imaging Criteria: Well-defined mass with pleural involvement, absence of diffuse pleural thickening.
Histopathological Criteria: Spindle cells with CD34 positivity, absence of epithelial markers.
Recurrence Risk Assessment:
- Score Components:
- Pleural origin: +1
- Morphology: +1 (benign vs. atypical)
- Size: +1 (≥10 cm)
- Hypercellularity: +1 (≥50%)
- Necrosis/hemorrhage: +1 (present)
- Mitotic activity: +1 (≥4 mitoses/10 HPF)
- Cutoff Score: ≤2 points: low risk; ≥3 points: high risk for recurrence 1.Differential Diagnosis:
Mesothelioma: Distinguished by history of asbestos exposure, diffuse pleural involvement, and different immunohistochemical profile (often positive for calretinin and WT1).
Hematologic Malignancies: Bone marrow involvement and specific hematologic markers help differentiate.
Benign Pleural Tumors: Histopathological examination confirms benign features lacking atypia and mitotic activity 23.Management
Surgical Resection
Primary Treatment: Complete surgical resection is the mainstay of treatment for both benign and malignant SFTPs 234.
- Approach: Thoracoscopic (VATS) or open thoracotomy, depending on tumor size and location.
- Outcome: Minimally invasive VATS is associated with shorter hospital stays (mean 7.2 days) and less morbidity compared to open thoracotomy 3.Adjuvant Therapy
High-Risk Malignant SFTPs: Consideration of adjuvant chemotherapy or radiotherapy in cases with high recurrence risk or aggressive features, though evidence is limited and benefits are not definitively established 24.
- Chemotherapy: No standard regimen; may include drugs targeting soft tissue sarcomas (e.g., doxorubicin, ifosfamide).
- Radiotherapy: Post-surgical adjuvant radiotherapy may be considered in selected cases with high-risk features 24.Monitoring and Follow-Up
Close Surveillance: Essential for high-risk patients, including regular imaging (CT scans) and clinical evaluations.
- Frequency: Every 3-6 months initially, tapering based on clinical stability and risk stratification 12.Complications
Recurrence: Primary concern, especially in high-risk patients identified by the recurrence score 1.
Respiratory Function Impairment: Postoperative complications may include atelectasis or persistent air leak, requiring prolonged chest tube drainage 3.
Metastasis: Rare but reported in malignant SFTPs, necessitating systemic evaluation if suspected 4.Prognosis & Follow-up
Benign SFTPs: Excellent prognosis with no recurrence reported in most cases post-complete resection 25.
Malignant SFTPs: Prognosis varies; high mitotic activity, necrosis, and atypical cytology correlate with poorer outcomes. Close follow-up is critical for early detection of recurrence or metastasis 12.
Follow-Up Intervals: Initial frequent monitoring (every 3-6 months) for high-risk patients, transitioning to annual evaluations in stable cases 12.Special Populations
Pediatrics: Limited data; management parallels adult cases with emphasis on complete resection and close follow-up 5.
Elderly Patients: Surgical risks must be carefully weighed against the benefits of resection; minimally invasive techniques may be preferred 3.
Comorbidities: Presence of significant comorbidities may influence surgical approach and postoperative management, necessitating multidisciplinary team involvement 3.Key Recommendations
Complete Surgical Resection: Essential for both benign and malignant SFTPs to achieve optimal outcomes (Evidence: Strong 234).
Use Recurrence Scoring System: Implement the validated scoring system to stratify patients into low and high risk for recurrence (Evidence: Moderate 1).
Consider VATS for Resection: Prefer video-assisted thoracoscopic surgery for minimally invasive approach, reducing morbidity (Evidence: Moderate 3).
Close Follow-Up for High-Risk Patients: Regular imaging and clinical evaluations every 3-6 months initially for high-risk patients (Evidence: Moderate 12).
Adjuvant Therapy in Selected Cases: Evaluate adjuvant chemotherapy or radiotherapy for high-risk malignant SFTPs, though evidence is limited (Evidence: Weak 24).
Monitor for Recurrence and Metastasis: Vigilant surveillance for signs of recurrence or metastasis, especially in malignant cases (Evidence: Expert opinion).
Multidisciplinary Approach: Involve thoracic surgery, oncology, and pulmonology teams for comprehensive management (Evidence: Expert opinion).
Consider Patient-Specific Factors: Tailor surgical approach and follow-up based on patient age, comorbidities, and overall health status (Evidence: Expert opinion).
Incidentally Detected Tumors: Ensure thorough evaluation even in asymptomatic patients to rule out malignancy (Evidence: Expert opinion).
FDG-PET for Malignancy Risk: Utilize FDG-PET for assessing high FDG uptake indicative of malignant potential in equivocal cases (Evidence: Moderate 4).References
1 Tapias LF, Mercier O, Ghigna MR, Lahon B, Lee H, Mathisen DJ et al.. Validation of a scoring system to predict recurrence of resected solitary fibrous tumors of the pleura. Chest 2015. link
2 Amorim E. Solitary fibrous tumor of the pleura: 3 case reports. Revista da Associacao Medica Brasileira (1992) 2015. link
3 Liu J, Cai C, Wang D, Chen H, Cheng L, Shao W et al.. Video-assisted thoracoscopic surgery (VATS) for patients with solitary fibrous tumors of the pleura. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010. link
4 Hara M, Kume M, Oshima H, Shibamoto Y, Iida A, Mori Y et al.. F-18 FDG uptake in a malignant localized fibrous tumor of the pleura. Journal of thoracic imaging 2005. link
5 Mezzetti M, Panigalli T, Giudice FL, Cappelli R, Giuliani L, Raveglia F et al.. Surgical experience of 15 solitary benign fibrous tumor of the pleura. Critical reviews in oncology/hematology 2003. link00174-9)